1. Home
  2. INLX vs VERU Comparison

INLX vs VERU Comparison

Compare INLX & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellinetics Inc.

INLX

Intellinetics Inc.

N/A

Current Price

$7.30

Market Cap

35.9M

Sector

Technology

ML Signal

N/A

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.27

Market Cap

41.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INLX
VERU
Founded
1996
1971
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.9M
41.7M
IPO Year
2013
1996

Fundamental Metrics

Financial Performance
Metric
INLX
VERU
Price
$7.30
$2.27
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
1.4K
51.8K
Earning Date
03-26-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$11,336.00
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
$15.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.42
$0.36
52 Week High
$15.72
$4.59

Technical Indicators

Market Signals
Indicator
INLX
VERU
Relative Strength Index (RSI) 34.57 40.52
Support Level N/A $2.15
Resistance Level $8.29 $2.70
Average True Range (ATR) 0.07 0.12
MACD -0.02 -0.03
Stochastic Oscillator 0.00 20.00

Price Performance

Historical Comparison
INLX
VERU

About INLX Intellinetics Inc.

Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Document Management and Document Conversion. The Document Management segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Conversion offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Conversion Segment.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: